ID   PUS3_HUMAN              Reviewed;         481 AA.
AC   Q9BZE2; B2RAM0; Q96D17; Q96J23; Q96NB4;
DT   27-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 3.
DT   18-JUN-2025, entry version 168.
DE   RecName: Full=tRNA pseudouridine(38/39) synthase;
DE            EC=5.4.99.45 {ECO:0000269|PubMed:27055666};
DE   AltName: Full=tRNA pseudouridine synthase 3;
DE   AltName: Full=tRNA pseudouridylate synthase 3;
DE   AltName: Full=tRNA-uridine isomerase 3;
GN   Name=PUS3; ORFNames=FKSG32;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Wang Y.-G., Gong L.;
RT   "Identification and characterization of FKSG32, a novel gene expressed in
RT   lung carcinoid.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-3 AND SER-46.
RC   TISSUE=Lung;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-3; SER-46 AND
RP   ASP-460.
RC   TISSUE=Pancreas, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-456 AND THR-468, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-466, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [7]
RP   INVOLVEMENT IN NEDMIGS, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=27055666; DOI=10.1007/s00439-016-1665-7;
RA   Shaheen R., Han L., Faqeih E., Ewida N., Alobeid E., Phizicky E.M.,
RA   Alkuraya F.S.;
RT   "A homozygous truncating mutation in PUS3 expands the role of tRNA
RT   modification in normal cognition.";
RL   Hum. Genet. 135:707-713(2016).
CC   -!- FUNCTION: Formation of pseudouridine at position 39 in the anticodon
CC       stem and loop of transfer RNAs. {ECO:0000269|PubMed:27055666}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=uridine(38/39) in tRNA = pseudouridine(38/39) in tRNA;
CC         Xref=Rhea:RHEA:42564, Rhea:RHEA-COMP:10117, Rhea:RHEA-COMP:10118,
CC         ChEBI:CHEBI:65314, ChEBI:CHEBI:65315; EC=5.4.99.45;
CC         Evidence={ECO:0000269|PubMed:27055666};
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- DISEASE: Neurodevelopmental disorder with microcephaly and gray sclerae
CC       (NEDMIGS) [MIM:617051]: An autosomal recessive disorder characterized
CC       by global developmental delay, hypotonia, profoundly impaired
CC       intellectual development with poor or absent language, mild
CC       microcephaly, abnormal visual fixation, and seizures in most patients.
CC       Affected individuals also have gray sclerae.
CC       {ECO:0000269|PubMed:27055666}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the tRNA pseudouridine synthase TruA family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF325689; AAG50280.1; -; mRNA.
DR   EMBL; AK055702; BAB70990.1; -; mRNA.
DR   EMBL; AK314251; BAG36917.1; -; mRNA.
DR   EMBL; BC004822; AAH04822.1; -; mRNA.
DR   EMBL; BC013427; AAH13427.2; -; mRNA.
DR   CCDS; CCDS8466.1; -.
DR   RefSeq; NP_001258914.1; NM_001271985.1.
DR   RefSeq; NP_112597.3; NM_031307.3.
DR   PDB; 8OKD; EM; 3.10 A; A/B=4-481.
DR   PDB; 9ENB; EM; 2.66 A; A/B=1-481.
DR   PDB; 9ENC; EM; 3.36 A; A/B=1-481.
DR   PDB; 9ENE; EM; 3.15 A; A/B=1-481.
DR   PDB; 9ENF; EM; 2.97 A; A/B=1-481.
DR   PDB; 9F9Q; EM; 6.50 A; A/B=4-481.
DR   PDBsum; 8OKD; -.
DR   PDBsum; 9ENB; -.
DR   PDBsum; 9ENC; -.
DR   PDBsum; 9ENE; -.
DR   PDBsum; 9ENF; -.
DR   PDBsum; 9F9Q; -.
DR   AlphaFoldDB; Q9BZE2; -.
DR   EMDB; EMD-16917; -.
DR   EMDB; EMD-16926; -.
DR   EMDB; EMD-19830; -.
DR   EMDB; EMD-19831; -.
DR   EMDB; EMD-19832; -.
DR   EMDB; EMD-19833; -.
DR   EMDB; EMD-19834; -.
DR   EMDB; EMD-19835; -.
DR   EMDB; EMD-19836; -.
DR   SMR; Q9BZE2; -.
DR   BioGRID; 123665; 8.
DR   FunCoup; Q9BZE2; 2782.
DR   IntAct; Q9BZE2; 5.
DR   STRING; 9606.ENSP00000227474; -.
DR   GlyGen; Q9BZE2; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; Q9BZE2; -.
DR   PhosphoSitePlus; Q9BZE2; -.
DR   BioMuta; PUS3; -.
DR   DMDM; 126302589; -.
DR   jPOST; Q9BZE2; -.
DR   MassIVE; Q9BZE2; -.
DR   PaxDb; 9606-ENSP00000227474; -.
DR   PeptideAtlas; Q9BZE2; -.
DR   ProteomicsDB; 79820; -.
DR   Pumba; Q9BZE2; -.
DR   Antibodypedia; 46038; 90 antibodies from 22 providers.
DR   DNASU; 83480; -.
DR   Ensembl; ENST00000227474.8; ENSP00000227474.3; ENSG00000110060.9.
DR   Ensembl; ENST00000530811.5; ENSP00000432386.1; ENSG00000110060.9.
DR   GeneID; 83480; -.
DR   KEGG; hsa:83480; -.
DR   MANE-Select; ENST00000227474.8; ENSP00000227474.3; NM_031307.4; NP_112597.4.
DR   UCSC; uc001qcy.3; human.
DR   AGR; HGNC:25461; -.
DR   CTD; 83480; -.
DR   DisGeNET; 83480; -.
DR   GeneCards; PUS3; -.
DR   HGNC; HGNC:25461; PUS3.
DR   HPA; ENSG00000110060; Low tissue specificity.
DR   MalaCards; PUS3; -.
DR   MIM; 616283; gene.
DR   MIM; 617051; phenotype.
DR   neXtProt; NX_Q9BZE2; -.
DR   OpenTargets; ENSG00000110060; -.
DR   Orphanet; 488627; Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome.
DR   PharmGKB; PA134874048; -.
DR   VEuPathDB; HostDB:ENSG00000110060; -.
DR   eggNOG; KOG2554; Eukaryota.
DR   GeneTree; ENSGT00950000183160; -.
DR   HOGENOM; CLU_014673_2_0_1; -.
DR   InParanoid; Q9BZE2; -.
DR   OMA; YFGWEYN; -.
DR   OrthoDB; 25767at2759; -.
DR   PAN-GO; Q9BZE2; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9BZE2; -.
DR   TreeFam; TF314428; -.
DR   PathwayCommons; Q9BZE2; -.
DR   Reactome; R-HSA-6782315; tRNA modification in the nucleus and cytosol.
DR   SignaLink; Q9BZE2; -.
DR   BioGRID-ORCS; 83480; 31 hits in 1172 CRISPR screens.
DR   GenomeRNAi; 83480; -.
DR   Pharos; Q9BZE2; Tbio.
DR   PRO; PR:Q9BZE2; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9BZE2; protein.
DR   Bgee; ENSG00000110060; Expressed in buccal mucosa cell and 208 other cell types or tissues.
DR   ExpressionAtlas; Q9BZE2; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0009982; F:pseudouridine synthase activity; EXP:Reactome.
DR   GO; GO:0003723; F:RNA binding; IEA:InterPro.
DR   GO; GO:0160154; F:tRNA pseudouridine(38/39) synthase activity; IMP:UniProtKB.
DR   GO; GO:1990481; P:mRNA pseudouridine synthesis; IBA:GO_Central.
DR   GO; GO:0006400; P:tRNA modification; TAS:Reactome.
DR   GO; GO:0031119; P:tRNA pseudouridine synthesis; IMP:UniProtKB.
DR   CDD; cd02569; PseudoU_synth_ScPus3; 1.
DR   FunFam; 3.30.70.580:FF:000007; tRNA pseudouridine synthase; 1.
DR   FunFam; 3.30.70.660:FF:000005; tRNA pseudouridine synthase; 1.
DR   Gene3D; 3.30.70.660; Pseudouridine synthase I, catalytic domain, C-terminal subdomain; 1.
DR   Gene3D; 3.30.70.580; Pseudouridine synthase I, catalytic domain, N-terminal subdomain; 1.
DR   HAMAP; MF_00171; TruA; 1.
DR   InterPro; IPR020103; PsdUridine_synth_cat_dom_sf.
DR   InterPro; IPR001406; PsdUridine_synth_TruA.
DR   InterPro; IPR020097; PsdUridine_synth_TruA_a/b_dom.
DR   InterPro; IPR020095; PsdUridine_synth_TruA_C.
DR   InterPro; IPR041707; Pus3-like.
DR   InterPro; IPR020094; TruA/RsuA/RluB/E/F_N.
DR   NCBIfam; TIGR00071; hisT_truA; 1.
DR   PANTHER; PTHR11142; PSEUDOURIDYLATE SYNTHASE; 1.
DR   PANTHER; PTHR11142:SF5; TRNA PSEUDOURIDINE(38_39) SYNTHASE; 1.
DR   Pfam; PF01416; PseudoU_synth_1; 1.
DR   SUPFAM; SSF55120; Pseudouridine synthase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Intellectual disability; Isomerase; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome;
KW   tRNA processing.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..481
FT                   /note="tRNA pseudouridine(38/39) synthase"
FT                   /id="PRO_0000057520"
FT   REGION          29..50
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        29..41
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        118
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250"
FT   BINDING         195
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         456
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         466
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         468
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VARIANT         3
FT                   /note="Y -> D (in dbSNP:rs622756)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030836"
FT   VARIANT         46
FT                   /note="A -> S (in dbSNP:rs549990)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030837"
FT   VARIANT         460
FT                   /note="E -> D (in dbSNP:rs3088241)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030838"
FT   CONFLICT        145
FT                   /note="F -> L (in Ref. 2; BAB70990)"
FT                   /evidence="ECO:0000305"
FT   HELIX           57..59
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          60..71
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           73..75
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           89..99
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           106..108
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          112..114
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          122..135
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           160..167
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          173..179
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   TURN            186..188
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          192..200
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           206..213
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           214..216
FT                   /evidence="ECO:0007829|PDB:8OKD"
FT   STRAND          218..221
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           230..232
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          238..250
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   TURN            257..259
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           260..262
FT                   /evidence="ECO:0007829|PDB:8OKD"
FT   STRAND          264..272
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           278..290
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          292..294
FT                   /evidence="ECO:0007829|PDB:9ENC"
FT   HELIX           298..302
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   TURN            305..307
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   STRAND          322..328
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   HELIX           338..368
FT                   /evidence="ECO:0007829|PDB:9ENB"
FT   TURN            398..401
FT                   /evidence="ECO:0007829|PDB:9ENE"
FT   HELIX           414..416
FT                   /evidence="ECO:0007829|PDB:9ENE"
SQ   SEQUENCE   481 AA;  55647 MW;  54B93653DB333535 CRC64;
     MAYNDTDRNQ TEKLLKRVRE LEQEVQRLKK EQAKNKEDSN IRENSAGAGK TKRAFDFSAH
     GRRHVALRIA YMGWGYQGFA SQENTNNTIE EKLFEALTKT RLVESRQTSN YHRCGRTDKG
     VSAFGQVISL DLRSQFPRGR DSEDFNVKEE ANAAAEEIRY THILNRVLPP DIRILAWAPV
     EPSFSARFSC LERTYRYFFP RADLDIVTMD YAAQKYVGTH DFRNLCKMDV ANGVINFQRT
     ILSAQVQLVG QSPGEGRWQE PFQLCQFEVT GQAFLYHQVR CMMAILFLIG QGMEKPEIID
     ELLNIEKNPQ KPQYSMAVEF PLVLYDCKFE NVKWIYDQEA QEFNITHLQQ LWANHAVKTH
     MLYSMLQGLD TVPVPCGIGP KMDGMTEWGN VKPSVIKQTS AFVEGVKMRT YKPLMDRPKC
     QGLESRIQHF VRRGRIEHPH LFHEEETKAK RDCNDTLEEE NTNLETPTKR VCVDTEIKSI
     I
//
